![Margarida Duarte](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: - $ in data 31/05/2026
Margarida Duarte is currently an Independent Director at Egetis Therapeutics AB since 2025 and serves as Global Chief Commercial Officer & Executive VP at Deciphera Pharmaceuticals, Inc. Formerly, Ms. Duarte was Vice President & Head-Commercial Canada at Alnylam Pharmaceuticals, Inc. Education includes graduate studies at ISCTE-Instituto Universitário de Lisboa and undergraduate studies at the University of Lisbon.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/12/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| EGETIS THERAPEUTICS AB | Direttore/Membro del Consiglio | 01/01/2025 |
| DECIPHERA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| Società | Posizione | Fine |
|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2021 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
ISCTE-Instituto Universitário de Lisboa
 ISCTE-Instituto Universitário de Lisboa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Lisbon
 University of Lisbon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Egetis Therapeutics AB
 Egetis Therapeutics AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Deciphera Pharmaceuticals, Inc.
 Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drug candidates to improve the lives of cancer patients | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
